Literature DB >> 25204290

Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomized, controlled study.

Minghang Wang1, Jiansheng Li, Suyun Li, Yang Xie.   

Abstract

This study aimed to evaluate the efficacy of comprehensive therapy based on traditional Chinese medicine (TCM) patterns on older patients with chronic obstructive pulmonary disease (COPD) through a fourcenter, open-label, randomized controlled trial. Patients were divided into the trial group treated using conventional western medicine and Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules, and Yi-Qi Zi-Shen granules based on TCM patterns respectively; and the control group treated using conventional western medicine. A total of 136 patients ≥ 65 years completed the study, with 63 patients comprising the trial group and 73 comprising the control group. After the six-month treatment and the 12-month follow-up period, significant differences were observed between the trial and control groups in the following aspects: frequency of acute exacerbation (P ≤ 0.040), duration of acute exacerbation (P = 0.034), symptoms (P ≤ 0.034), 6-min walking distance (6MWD) (P ≤ 0.039), dyspnea scale (P ≤ 0.036); physical domain (P ≤ 0.019), psychological domain (P ≤ 0.033), social domain (P ≤ 0.020), and environmental domain (P ≤ 0.044) of the WHOQOL-BREF questionnaire; and daily living ability domain (P ≤ 0.007), social activity domain (P ≤ 0.018), depression symptoms domain (P ≤ 0.025), and anxiety symptoms domain (P ≤ 0.037) of the COPD-QOL. No differences were observed between the trial and control groups with regard to FVC, FEV1, and FEV1%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25204290     DOI: 10.1007/s11684-014-0360-0

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  25 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  Less smoke, more fire: What's new for you in the latest COPD guidelines?

Authors:  Alan Kaplan; Paul Hernandez; Denis O'Donnell
Journal:  Can Fam Physician       Date:  2008-05       Impact factor: 3.275

3.  Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study.

Authors:  Jian-Sheng Li; Su-Yun Li; Xue-Qing Yu; Yang Xie; Ming-Hang Wang; Ze-Geng Li; Nian-Zhi Zhang; Su-Ju Shao; Yi-Jie Zhang; Lin Zhu; Lian-Xiang Guo; Yun-Ping Bai; Yan-Fang Wang
Journal:  J Ethnopharmacol       Date:  2011-09-05       Impact factor: 4.360

4.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors:  Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease.

Authors:  Anne E Holland; Catherine J Hill; Tshepo Rasekaba; Annemarie Lee; Matthew T Naughton; Christine F McDonald
Journal:  Arch Phys Med Rehabil       Date:  2010-02       Impact factor: 3.966

6.  Impact on patients' health status following early identification of a COPD exacerbation.

Authors:  J Bourbeau; G Ford; H Zackon; N Pinsky; J Lee; G Ruberto
Journal:  Eur Respir J       Date:  2007-08-22       Impact factor: 16.671

Review 7.  COPD exacerbations: definitions and classifications.

Authors:  S Burge; J A Wedzicha
Journal:  Eur Respir J Suppl       Date:  2003-06

Review 8.  Epidemiology of chronic obstructive pulmonary disease: a literature review.

Authors:  Catherine E Rycroft; Anne Heyes; Lee Lanza; Karin Becker
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-20

9.  Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study.

Authors:  Su-yun Li; Jian-sheng Li; Ming-hang Wang; Yang Xie; Xue-qing Yu; Zi-kai Sun; Li-jun Ma; Wei Zhang; Hai-long Zhang; Fan Cao; Ying-chao Pan
Journal:  BMC Complement Altern Med       Date:  2012-10-29       Impact factor: 3.659

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more
  4 in total

1.  Effect of Radix Stemonae concentrated decoction on the lung tissue pathology and inflammatory mediators in COPD rats.

Authors:  Zhenwei Wang; Wenlan Yang; Peilan Yang; Beilan Gao; Lei Luo
Journal:  BMC Complement Altern Med       Date:  2016-11-10       Impact factor: 3.659

2.  Chinese Herbal Medicine Versus Placebo for the Treatment Of Chronic Obstructive Pulmonary Disease: A Protocol of Systematic Review and Meta-analysis.

Authors:  Chan Xiong; Yu Li; Yan Zeng; Hua Wei; Guang-Tong Zhuang; Lin Li; Li-Hong Zhao; Chen-Yi Li; Er-Qi Qin; Juan-Juan Fu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF-κB Signaling.

Authors:  Fanli Jin; Lanxi Zhang; Kai Chen; Yufang Miao; Yang Liu; Yange Tian; Jiansheng Li
Journal:  Biomed Res Int       Date:  2022-05-09       Impact factor: 3.411

4.  The Clinical Efficiency and the Mechanism of Sanzi Yangqin Decoction for Chronic Obstructive Pulmonary Disease.

Authors:  Mengqi Wang; Wenwen Gu; Fuguang Kui; Fan Gao; Yuji Niu; Wenwen Li; Yaru Zhang; Lijuan Guo; Shengnan Geng; Gangjun Du
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-10       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.